Suppr超能文献

重组人 PH20:使用健康受试者对普通人群中反应性抗体流行率的基线分析。

Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy Subjects.

机构信息

Immunology and Cell Biology, Halozyme Therapeutics, Inc., 11388 Sorrento Valley Road, San Diego, CA, 92121, USA.

出版信息

BioDrugs. 2018 Feb;32(1):83-89. doi: 10.1007/s40259-018-0260-y.

Abstract

BACKGROUND

Recombinant human PH20 (rHuPH20) is used to depolymerize hyaluronan in the subcutaneous space, increasing the dispersion and absorption of co-administered drugs. While ~ 5 to 10% of rHuPH20 treatment-naïve healthy volunteers have demonstrated rHuPH20-reactive antibodies, associations with age, sex, fertility, and immune disorders remain unknown.

OBJECTIVES

Using demographically diverse healthy volunteers, we assessed the prevalence of rHuPH20-reactive antibodies in the general population and potential associations with fertility and autoimmunity diseases.

METHODS

In total, 896 subjects aged ≥ 12 years (767 adults; 129 children) without prior exposure to rHuPH20 were enrolled. A demographic and limited medical history review was performed, and K3-EDTA-anticoagulated plasma was analyzed for rHuPH20-reactive antibodies using a bridging immunoassay.

RESULTS

Adult and pediatric positivity rates for rHuPH20-reactive antibodies were 5.2% (40/767) and 1.6% (2/129), respectively. Titers ranged from 5 to 2560 (median 30). In five antibody-positive subjects from whom repeated samples were available, antibody titers remained unchanged or decreased fourfold over periods up to 590 days. The prevalence of rHuPH20-reactive antibodies significantly increased with age (p = 0.0006) and was significantly higher in males than in females (p = 0.0010). Men who had fathered children had a significantly increased prevalence of rHuPH20-reactive antibodies than men who had not (p = 0.0036), whereas the rate of childbearing was not significantly different between rHuPH20 antibody-positive and -negative women. The prevalence between racial/ethnic groups was not significantly different, nor was the presence/absence of an autoimmune disorder.

CONCLUSIONS

Approximately 1/20 of the adult population had rHuPH20-reactive antibodies. The reason remains unknown; however, no evidence for a negative effect on fertility or association with autoimmune disease was demonstrated.

摘要

背景

重组人 PH20(rHuPH20) 用于分解皮下空间中的透明质酸,增加同时给予的药物的分散和吸收。虽然 ~5%至 10%的 rHuPH20 治疗初治的健康志愿者表现出 rHuPH20 反应性抗体,但与年龄、性别、生育能力和自身免疫性疾病的关联仍不清楚。

目的

使用人口统计学上多样化的健康志愿者,我们评估了 rHuPH20 反应性抗体在普通人群中的流行率,并评估了与生育能力和自身免疫性疾病的潜在关联。

方法

共纳入 896 名年龄≥12 岁(767 名成人;129 名儿童)且无 rHuPH20 暴露史的受试者。进行了人口统计学和有限的病史回顾,并使用桥联免疫分析法分析 K3-EDTA 抗凝血浆中的 rHuPH20 反应性抗体。

结果

成人和儿科 rHuPH20 反应性抗体的阳性率分别为 5.2%(40/767)和 1.6%(2/129),滴度范围为 5 至 2560(中位数 30)。在 5 名可重复获得样本的抗体阳性受试者中,抗体滴度在长达 590 天的时间内保持不变或降低四倍。rHuPH20 反应性抗体的阳性率随年龄显著增加(p=0.0006),男性显著高于女性(p=0.0010)。有生育能力的男性 rHuPH20 反应性抗体的阳性率显著高于无生育能力的男性(p=0.0036),而 rHuPH20 抗体阳性和阴性女性的生育率没有显著差异。不同种族/族裔群体之间的阳性率没有显著差异,自身免疫性疾病的存在与否也没有显著差异。

结论

约 1/20 的成年人口具有 rHuPH20 反应性抗体。原因尚不清楚;然而,没有证据表明对生育能力有负面影响或与自身免疫性疾病有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8070/5814530/c7b14ffda734/40259_2018_260_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验